PTK7 expression in triple-negative breast cancer

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3759-3764

  Ataseven, Beyhan ^a,b   Angerer, Regina ^a   Kates, Ronald ^c   Gunesch, Angela ^a   Knyazev, Pjotr ^d   Högel, Bernhard ^e   Becker, Clemens ^e   Eiermann, Wolfgang ^f   Harbeck, Nadia ^c  

^a Redcross Women's Hospital   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e Department of Obstetrics/Gynecology   (Germany)

^f Department of Gynecology and Oncology   (Germany)

Author keywords

Anthracycline resistance; Prognosis; PTK7; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 7; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

ANTHRACYCLINE RESISTANCE; PROGNOSIS; PTK7; TRIPLE-NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84884991467     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mossie K, Jallal B, Alves F, Sures I, Plowman GD and Ullrich A: Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. Oncogene 11(10): 2179-2184, 1995.
2. Park SK, Lee HS and Lee ST: Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG. J Biochem 119(2): 235-239, 1996.
3. Jung JW, Ji AR, Lee J, Kim UJ and Lee ST: Organization of the human PTK7 gene encoding a receptor protein tyrosine kinaselike molecule and alternative splicing of its mRNA. Biochim Biophys Acta 1579(2-3): 153-163, 2002.
4. Lhoumeau AC, Puppo F, Prebet T, Kodjabachian L and Borg JP: PTK7: A cell polarity receptor with multiple facets. Cell Cycle, 10(8): 1233-1236, 2011.
5. Takemaru KI, Ohmitsu M and Li FQ: An oncogenic hub: Betacatenin as a molecular target for cancer therapeutics. Handb Exp Pharmacol 186: 261-284, 2008.
6. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH: WNT/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome. Am J Pathol 176(6): 2911-2920, 2010.
7. Katoh M: WNT/PCP signaling pathway and human cancer (review). Oncol Rep 14(6): 1583-1588, 2005.
8. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho J: β-Catenin pathway activation in breast cancer is associated with triplenegative phenotype but not with CTNNB1 mutation. Mod Pathol 24(2): 209-231, 2011.
9. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J and Brown P: Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 15(20): 6327-6340, 2009.
10. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW and Vogelstein B: A phosphatase associated with metastasis of colorectal cancer. Science 294(5545): 1343-1346. 2001.
11. Prebet T, Lhoumeau AC, Arnoulet C, Aulas A, Marchetto S, Audebert S, Puppo F, Chabannon C, Sainty D, Santoni MJ, Sebbagh M, Summerour V, Huon Y, Shin WS, Lee ST, Esterni B, Vey N and Borg JP: The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood 116(13): 2315-2323, 2010.
12. Lin Y, Zhang LH, Wang XH, Xing XF, Cheng XJ, Dong B, Hu Y, Du H, Li YA, Zhu YB, Ding N, Du YX, Li JY and Ji J: PTK7 as a novel marker for favorable gastric cancer patient survival. J Surg Oncol 106(7): 880-886, 2012.
13. Gorringe KL, Boussioutas A and Bowtell DD: Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chrom Cancer 42(3): 247-259, 2005.
14. Gobble RM, Qin LX, Brill ER, Angeles CV, Ugras S, O'Connor RB, Moraco NH, Decarolis PL, Antonescu C and Singer S: Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res 71(7): 2697-705, 2011.
15. Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, Kuwano H, Takahashi T and Mitsudomi T: Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 22(5): 811-819, 2004.
16. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1): 4429-34, 2007.
17. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U and Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J NatCancer Inst 100(1): 14-20, 2008.
18. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 8(3): 138-140, (in German), 1987.
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1): 118-145, 2007.